Healthcare

Axsome Therapeutics Recognizes Mental Illness Awareness Week Along with the National Advocacy Community

NEW YORK, Oct. 09, 2025 (GLOBE NEWSWIRE) -- Axsome Therapeutics, Inc. (NASDAQ: AXSM), a biopharmaceutical company leading a new era…

3 months ago

Tilray Brands Reports Strong First Quarter Fiscal 2026 Results, Highlighting Continued Growth with Record Q1 Net Revenue of $210 Million and Net Income

Operational Efficiencies and Focus on Profitability Drove Net Income of $1.5 Million, Adjusted EBITDA Increased 9% to $10 Million and Net…

3 months ago

Bluejay Diagnostics and SanyoSeiko Expand Strategic Partnership to Advance Commercialization of Symphony Platform

ACTON, Mass. and YAMANASHI, Japan, Oct. 09, 2025 (GLOBE NEWSWIRE) -- Bluejay Diagnostics, Inc. (NASDAQ: BJDX) (“Bluejay”), a medical diagnostics…

3 months ago

Akero Therapeutics to be Acquired by Novo Nordisk for up to $5.2 Billion

Shareholders to Receive $54 Per Share in Cash and CVR of $6 Per Share  Advances Akero’s Mission of Bringing Novel…

3 months ago

Novo Nordisk to acquire Akero Therapeutics and its promising phase 3 FGF21 analogue to expand MASH portfolio

Acquisition adds potential first- and best-in-class asset, enhancing Novo Nordisk’s portfolio for treatment of MASH, one of the most prevalent…

3 months ago

Italfarmaco Appoints Francesco Di Marco as Chief Executive Officer

MILAN, Italy, October 09, 2025 – Italfarmaco S.p.A. today announced that Dr. Francesco Di Marco has been appointed as Chief…

3 months ago

Advantech AOM-5721 Combines SMARC Design and Qualcomm Dragonwing™ QCS6490 for Next-Gen Edge AI

TAIPEI, Oct. 9, 2025 /PRNewswire/ -- Advantech (TWSE: 2395), a global leader in edge computing and AI solutions, is proud…

3 months ago

EX DEA Administrator Anne Milgram’s “Swampy” Legacy: No-Bid Contracts, No Marijuana Reform, and No Accountability

MMJ BioPharma CEO Duane Boise summed it up bluntly:"Milgram's DEA was a monument to incompetence and indifference - and patients…

3 months ago

BioNxt Completes “Fast-Track” US Track One Patent Filing for Sublingual Delivery of Cladribine for the Treatment of Multiple Sclerosis

VANCOUVER, BC / ACCESS Newswire / October 9, 2025 / BioNxt Solutions Inc. ("BioNxt" or the "Company") (CSE:BNXT)(OTCQB:BNXTF)(FSE:BXT), a bioscience…

3 months ago

Genflow Biosciences PLC Announces Update, Equity Issue and PDMR Notification

THE INFORMATION CONTAINED WITHIN THIS ANNOUNCEMENT IS DEEMED BY THE COMPANY TO CONSTITUTE INSIDE INFORMATION AS STIPULATED UNDER THE MARKET…

3 months ago